Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CSPC PHARMA (01093.HK) SYS6051 Receives US FDA Approval to Commence Clinical Trials
Recommend 7 Positive 14 Negative 1 |
||||
|
||||
|
CSPC PHARMA (01093.HK) announced that SYS6051, an antibody-drug conjugate (ADC) developed by the Group, has received approval from the US Food and Drug Administration (FDA) to commence clinical trials. The approved indication for this trial is advanced solid tumors. SYS6051 is an antibody-drug conjugate targeting human tissue factor. It binds to tissue factor on the surface of tumor cells, enters the cells through endocytosis and releases cytotoxic agents to eliminate tumor cells. In April this year, it was approved by the National Medical Products Administration of China to commence clinical trials. (de/d) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
